Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Amortization of Deferred Charges: 2021-2024

Historic Amortization of Deferred Charges for Compass Therapeutics (CMPX) over the last 4 years, with Dec 2024 value amounting to -$1.7 million.

  • Compass Therapeutics' Amortization of Deferred Charges fell 34.89% to -$375,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$747,000, marking a year-over-year increase of 65.94%. This contributed to the annual value of -$1.7 million for FY2024, which is 48.82% up from last year.
  • According to the latest figures from FY2024, Compass Therapeutics' Amortization of Deferred Charges is -$1.7 million, which was up 48.82% from -$3.2 million recorded in FY2023.
  • Compass Therapeutics' 5-year Amortization of Deferred Charges high stood at $41,000 for FY2021, and its period low was -$3.2 million during FY2023.
  • Its 3-year average for Amortization of Deferred Charges is -$1.9 million, with a median of -$1.7 million in 2024.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first slumped by 2,053.66% in 2022, then surged by 48.82% in 2024.
  • Over the past 4 years, Compass Therapeutics' Amortization of Deferred Charges (Yearly) stood at $41,000 in 2021, then tumbled by 2,053.66% to -$801,000 in 2022, then crashed by 302.75% to -$3.2 million in 2023, then spiked by 48.82% to -$1.7 million in 2024.